Drug Description in Trials / DrugBank / KEGG DRUG
Search results
Showing 1 to 7 of 7 descriptions
| No. | Drug (Description in trials) | DrugBank | KEGG DRUG | KEGG GENES | KEGG PATHWAY | Disease ID | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Combination Product: mavrilimumab | [1] Mavrilimumab Mavrilimumab | [1] Mavrilimumab
Mavrilimumab
💬1. Combination Product: mavrilimumab
| [1] CSF2RA CSF2RA 💬1. Combination Product: mavrilimumab
| [4] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 [4] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, ... | [1] 41 41 💬1. Combination Product: mavrilimumab
| ||||||||||||
| 2 | MAVRILIMUMAB | [1] Mavrilimumab Mavrilimumab | [1] Mavrilimumab
Mavrilimumab
💬2. MAVRILIMUMAB
| [1] CSF2RA CSF2RA 💬2. MAVRILIMUMAB
| [4] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 [4] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, ... | [2] 41 41, 46 💬
| ||||||||||||
| 3 | Mavrilimumab 10 mg | [1] Mavrilimumab Mavrilimumab | [1] Mavrilimumab
Mavrilimumab
💬3. Mavrilimumab 10 mg
| [1] CSF2RA CSF2RA 💬3. Mavrilimumab 10 mg
| [4] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 [4] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, ... | [1] 46 46 💬3. Mavrilimumab 10 mg
| ||||||||||||
| 4 | Mavrilimumab 100 mg | [1] Mavrilimumab Mavrilimumab | [1] Mavrilimumab
Mavrilimumab
💬4. Mavrilimumab 100 mg
| [1] CSF2RA CSF2RA 💬4. Mavrilimumab 100 mg
| [4] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 [4] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, ... | [1] 46 46 💬4. Mavrilimumab 100 mg
| ||||||||||||
| 5 | Mavrilimumab 150 mg | [1] Mavrilimumab Mavrilimumab | [1] Mavrilimumab
Mavrilimumab
💬5. Mavrilimumab 150 mg
| [1] CSF2RA CSF2RA 💬5. Mavrilimumab 150 mg
| [4] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 [4] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, ... | [1] 46 46 💬5. Mavrilimumab 150 mg
| ||||||||||||
| 6 | Mavrilimumab 30 mg | [1] Mavrilimumab Mavrilimumab | [1] Mavrilimumab
Mavrilimumab
💬6. Mavrilimumab 30 mg
| [1] CSF2RA CSF2RA 💬6. Mavrilimumab 30 mg
| [4] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 [4] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, ... | [1] 46 46 💬6. Mavrilimumab 30 mg
| ||||||||||||
| 7 | Mavrilimumab 50 mg | [1] Mavrilimumab Mavrilimumab | [1] Mavrilimumab
Mavrilimumab
💬7. Mavrilimumab 50 mg
| [1] CSF2RA CSF2RA 💬7. Mavrilimumab 50 mg
| [4] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 [4] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, ... | [1] 46 46 💬7. Mavrilimumab 50 mg
|